4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $32000 | -$12M | -1225.0% | -13381.3% | — | — | $3000 |
| 2024 | — | -$25M | — | — | — | — | $2M |
| 2023 | — | -$4M | — | — | — | — | $1000 |
| 2022 | $50000 | -$7M | 0.0% | -6808.0% | — | — | $2000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $7000 | -$2M | 0.0% | -32700.0% | — | — | $20000 |
| Dec '25 | $7000 | $5M | -5928.6% | -16714.3% | — | — | $3000 |
| Sep '25 | $18000 | -$1M | 94.4% | -5266.7% | — | — | $12000 |
| Jun '25 | $7000 | -$14M | -57.1% | -16471.4% | — | — | $624000 |
| Mar '25 | — | -$1M | — | — | — | — | $1M |
| Dec '24 | — | -$27M | — | — | — | — | $2M |
| Sep '24 | — | $4M | — | — | — | — | $3M |
| Jun '24 | — | -$889000 | — | — | — | — | $2000 |
| Mar '24 | — | -$962000 | — | — | — | — | $2000 |
| Dec '23 | — | -$1M | — | — | — | — | $1000 |
| Sep '23 | — | -$1M | — | — | — | — | $201000 |
| Jun '23 | — | -$1M | — | — | — | — | $3000 |
| Mar '23 | — | -$849000 | — | — | — | — | — |
| Dec '22 | $0 | -$3M | — | — | — | — | $2000 |
| Sep '22 | $0 | -$2M | — | — | — | — | — |
| Jun '22 | $50000 | -$799000 | 0.0% | -1500.0% | — | — | — |
How the market has priced IBO against its own fundamentals since 2024-09 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, IMPACT BIOMEDICAL INC.'s revenue has declined 13.8% per year. These are computed facts, not advice.
As of FY2025, IMPACT BIOMEDICAL INC. reported — of total debt against $3000 of cash; operating income covered interest expense -5.4×.
In FY2025, gross margin was -1225.0%, operating margin -13381.3%, and net margin -36993.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.